Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 4105 - 4112 of 11613 results
SEC Guidance on Key Performance Indicators and Metrics in MD&A and Three New MD&A C&DIs
February 26, 2020| Advisory| Viewpoint
MintzEdge Entrepreneur Perspective: Startup Space
February 25, 2020| Podcast| Viewpoint
340B Ceiling Price Transparency – HRSA Now Requiring Pharmaceutical Manufacturers to Issue Refunds to Covered Entities for Overcharges
February 24, 2020| Blog| Viewpoint
Does Epic’s CEO Have A Point On Privacy?
February 24, 2020| News
Analysis of Modified Attorney General Regulations to CCPA – Part 5: Discriminatory Practices and Financial Incentives
February 21, 2020| Blog| Viewpoint
Algorithmic Accountability Act
February 20, 2020| Video| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.